Sigrid Therapeutics, based in Stockholm, Sweden, is a leading health and technology company focused on preventing and treating lifestyle diseases such as diabetes and obesity. With its innovative medical device SiPore®, Sigrid offers a safe and natural solution to reduce blood sugar levels in people at risk of diabetes, pre-diabetics and people newly diagnosed with type 2 diabetes. SiPore® works by being consumed orally as a tasteless and odorless powder that, along with water, acts in the gastrointestinal tract to mechanically improve metabolic health.

Sigrid Therapeutics combines cutting-edge materials technology with clinical research to create solutions that not only improve individual health outcomes but also contribute to a more sustainable treatment of global health challenges. SiPore® is designed to act locally in the gut without being absorbed into the body, ensuring both efficacy and safety. The product has undergone extensive clinical testing confirming its ability to safely reduce blood sugar levels and improve metabolic parameters.

Sigrid Therapeutics is a pioneer in its niche, with strong research collaborations and a clear vision to radically change the way we prevent and treat lifestyle diseases on a global scale. They strive to deliver solutions that are not only effective but also user-friendly and accessible to a wide range of patients.